125 related articles for article (PubMed ID: 38497158)
1. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E; Ferrero S; Bommier C; Drandi D; Ferrante M; Bouabdallah K; Carras S; Gini G; Camus V; Mancuso S; Marcheselli L; Ferrari A; Merli M; Tessoulin B; Stelitano C; Beldjord K; Roti G; Jardin F; Castagnari B; Palombi F; Baseggio L; Traverse-Glehen A; Tripodo C; Liberati AM; Parolini M; Usai S; Patti C; Federico M; Musso M; Ladetto M; Zucca E; Thieblemont C
Haematologica; 2024 Mar; ():. PubMed ID: 38497158
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
4. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
[TBL] [Abstract][Full Text] [Related]
5. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Hsu A; Kurt H; Zayac AS; Olszewski AJ
Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
7. Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly.
Junlén HR; Sonnevi K; Lindén O; Hellström M; Scivetti MV; Olsson M; Tufvesson I; Johansson AS; Wahlin BE
EJHaem; 2023 Aug; 4(3):647-655. PubMed ID: 37601869
[TBL] [Abstract][Full Text] [Related]
8. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
9. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
10. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Cheah CY; Opat S; Trotman J; Marlton P
Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine.
Manner H; Jung B; Tonassi L; Hackenberg U; Plum N; Josten KM; Kirchmaier CM; Frickhofen N
Am J Med Sci; 2008 May; 335(5):394-7. PubMed ID: 18480659
[TBL] [Abstract][Full Text] [Related]
13. Unusual Course of Splenic Marginal Zone Lymphoma.
Tun NT; Mi K; Smith J
World J Oncol; 2013 Oct; 4(4-5):205-209. PubMed ID: 29147357
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Gressin R; Daguindau N; Tempescul A; Moreau A; Carras S; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Pignon JM; Corm S; Banos A; Mounier C; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouadallah K; Amorin S; Garidi R; Voillat L; Joly B; Celigny PS; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Le Gouill S; Callanan MB;
Haematologica; 2019 Jan; 104(1):138-146. PubMed ID: 30171024
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
[TBL] [Abstract][Full Text] [Related]
16. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.
Iannitto E; Luminari S; Tripodo C; Mancuso S; Cesaretti M; Marcheselli L; Merli F; Stelitano C; Carella AM; Fragasso A; Montechiarello E; Ricciuti G; Pulsoni A; Paulli M; Franco V; Federico M
Leuk Lymphoma; 2015; 56(12):3281-7. PubMed ID: 25791121
[TBL] [Abstract][Full Text] [Related]
17. Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases.
Tsutsumi Y; Ito S; Nagai J; Tateno T; Teshima T
Mol Clin Oncol; 2021 Oct; 15(4):208. PubMed ID: 34466224
[TBL] [Abstract][Full Text] [Related]
18. Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database.
Dote S; Inose R; Goto R; Kobayashi Y; Muraki Y
Hematol Oncol; 2023 Aug; 41(3):354-362. PubMed ID: 36792059
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
20. Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
Lyu R; Wang T; Wang Y; Xiong W; Wang H; Yan Y; Wang Q; Liu W; An G; Huang W; Sui W; Xu Y; Zou D; Wang J; Qiu L; Yi S
Br J Haematol; 2021 Sep; 194(5):862-869. PubMed ID: 34328213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]